The biopharmaceutical industry has more commonly been seen as a villian in recent years, but it has played a heroic role in responding to the COVID-19 pandemic – rising to meet challenges from research and development to manufacturing, all in unprecedented timelines with new levels of collaboration and virtually unrestricted budgets. As new treatments reach patients and vaccines get closer, will there be a goodwill benefit for the industry? Scrip spoke with several industry execs and outside observers about the potential for pharma to reset its reputation. (Also see "Can Pharma Rebuild Its Reputation? COVID-19 Means A Big Responsibility, And Opportunity" - Scrip, 30 October, 2020.) Below are some of their responses.
What COVID Spotlight Means For Pharma – In Their Own Words
Observers Weigh In On The Impact Pandemic Response Will Have On Industry's Reputation
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
More from COVID-19
More from Scrip
• By
As CEO Anderson backs high prices for innovative drugs in Europe
• By
Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.
• By
The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.